UCB has been granted a patent for antibody molecules targeting IL-17A and IL-17F. The patent also covers therapeutic uses and methods for producing these antibodies. Claim 1 specifies an expression vector with a specific nucleic acid sequence. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights UCB SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Dual-specific il-17a and il-17f antibody for therapy

Source: United States Patent and Trademark Office (USPTO). Credit: UCB SA

A recently granted patent (Publication Number: US11919950B2) discloses an expression vector containing specific nucleic acid sequences, as outlined in SEQ ID NO: 14. This vector is further enhanced by the inclusion of another nucleic acid sequence from SEQ ID NO: 10, which aims to improve its functionality and efficiency.

The patent also covers the use of host cells containing the aforementioned expression vector. Methods for culturing these host cells under suitable conditions to facilitate the expression of the nucleic acids are detailed in the claims. Additionally, variations in the host cells, such as the presence of SEQ ID NO: 10 in the expression vector, are also considered, with corresponding methods for culturing and expression outlined in the patent. These claims highlight the innovative approach taken in the development of expression vectors and their application in host cells for efficient nucleic acid expression.

To know more about GlobalData’s detailed insights on UCB, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies